Evidence map›Paper›PMID 41193417›Full record

Trial reportNature communications2025

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Chee Khoon Lee, Apriliana E R Kartikasari, Nirashaa T Bound, Katherine E Francis, Kristy Shield-Artin, Justin Bedo, Ksenija Nesic, Katrina Diamante, Rachel L O'Connell, Mutsa Madondo and 25 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Chee Khoon LeeNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia. chee.lee@sydney.edu.au.ORCID http://orcid.org/0000-0003-2955-9820
Apriliana E R Kartikasari *Accelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Nirashaa T Bound *Accelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.ORCID http://orcid.org/0009-0006-5847-0277
Katherine E FrancisNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-8555-0161
Kristy Shield-ArtinWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-3969-9846
Justin BedoWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-5704-0212
Ksenija NesicWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-9972-9819
Katrina DiamanteNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Rachel L O'ConnellNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Mutsa MadondoAccelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Momodou CoxAccelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Claire DaviesAustralia and New Zealand Gynaecological Oncology Group, Camperdown, NSW, Australia.ORCID http://orcid.org/0000-0001-8651-0914
Cyril DeceneuxAccelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Georgia GoodchildAccelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
Andrew JarrattWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Emily CassarAccelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.ORCID http://orcid.org/0009-0000-3214-4613
Hina AmerAccelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.ORCID http://orcid.org/0000-0002-6359-4956
U G Imalki U KariyawasamWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-3540-8607
Yeh Chen LeeNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Janine LombardNewcastle Private Hospital, New Lambton Heights, NSW, Australia.
Sally Baron-HayDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia.ORCID http://orcid.org/0000-0002-9748-1458
Yoland AntillDepartment of Medical Oncology, Peninsula Health, Frankston, VIC, Australia.
Catherine ShannonMater Cancer Care Centre, South Brisbane, QLD, Australia.
Sudarshan Selva-NayagamDepartment of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Philip BealeDepartment of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
Danka ZebicNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Sandy SimonNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0005-1274-2575
Anneliese LinakerNHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Michael A QuinnOncology Unit, Royal Women's Hospital and University of Melbourne, Melbourne, VIC, Australia.
Anthony T PapenfussWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-1102-8506
Matthew J WakefieldWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-6624-4698
Cassandra J VandenbergWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-8891-8873
Michael Friedlander *Department of Medical Oncology, Prince of Wales Hospital and Royal Hospital for Women, Randwick, NSW, Australia.ORCID http://orcid.org/0000-0003-3090-795X
Clare L Scott *Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-3689-5956
Magdalena Plebanski *Accelerator for Translational Research and Clinical Trials (ATRACT) Centre, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.ORCID http://orcid.org/0000-0001-6889-3667

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n = 114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N = 71) as compared to the proficient (HRP) (N = 29) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N = 58) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N = 46). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are BRCA wild-type, including HRP patients.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideOvarian NeoplasmsPhthalazinesPiperazinesAdultAgedFemaleHumansMiddle AgedPrognosisProgression-Free SurvivalAntibodies, MonoclonalCyclophosphamidedurvalumabolaparibPhthalazinesPiperazines

Identifiers

PMID41193417
PMCPMC12589412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.